The recent global outbreak of severe acute respiratory syndrome (SARS) has quickly gained notoriety as a newly emerging infectious disease. The etiologic agent was identified as a coronavirus (SARS-CoV) that is not closely related to any of the previously characterized coronaviruses ([@R1]*,*[@R2]). As of September 26, 2003, a total of 8,098 probable cases of SARS have occurred with 774 deaths.

No antiviral treatments are currently available against SARS-CoV. SARS cases have been treated symptomatically according to the severity of the illness. A treatment protocol consisting of antibacterial agents and a combination of ribavirin and methylprednisolone was recently proposed. However, the therapeutic value of ribavirin remains uncertain because it has no activity against SARS-CoV in vitro. Molecular modeling studies suggest that rhinovirus 3C^pro^ inhibitors may be useful for SARS therapy, but results of recent in vitro testing of the lead molecule, AG7088, were negative ([@R3]).

Previous studies showed that some coronaviruses, including avian infectious bronchitis virus, murine hepatitis virus, and human coronavirus 229E, are susceptible to type I interferons in vitro or in vivo ([@R4]*--*[@R7]). Therefore, we evaluated the in vitro efficacy of a recombinant human type I interferon (IFN), IFN-β 1a (Serono International, Geneva, Switzerland) against three different isolates of SARS-CoV (Tor2 and Tor7 and Urbani) using yield reduction assays. The IFN-β 1a preparation employed in this study was selected because it is currently used as part of the most effective treatment regimen for relapsing forms of multiple sclerosis ([@R8]), and more importantly, because it was shown to have antiviral activity (as measured in a vesicular stomatitis virus cytopathic assay system) 14 times greater than the currently available treatment using IFN-β 1b ([@R9]).

In the current study, Vero E-6 cells were treated with concentrations (5,000 to 500,000 IU/mL) of IFN-β 1a either 24 h before or 1 h after inoculation with the SARS-CoV (m.o.i. 0.1 PFU/cell), and monitored for cytopathic effect and production of infectious SARS-CoV at 24, 48, and 72 h postinfection. Inhibition of the SARS-CoVs by IFN-β 1a was dependent on both time of drug administration and time of culture sampling after SARS-CoV infection. Production of infectious SARS-CoV was potently inhibited (≥99.5% or 2.00 log10 PFU/mL) at 24 h postinfection. by pretreatment of Vero E-6 cells with IFN-β 1a at all concentrations tested ([Figure 1](#F1){ref-type="fig"}). By 72 h postinfection, inhibition of SARS-CoV production by IFN-β 1a had declined for all three SARS-CoVs, with inhibition ([\>]{.ul}70%) being detected in the Tor7 ([Figure 1](#F1){ref-type="fig"}) and Urbani isolates (data not shown). IFN-β 1a was somewhat less effective at inhibiting SARS-CoV replication when employed after infection of cultures ([Figure 1](#F1){ref-type="fig"}). Nonetheless, production of infectious SARS-CoVs was considerably reduced (≥90% or 1.00 log10 PFU/mL) at 24 and 48 h postinfection. Protection of Vero E-6 monolayers against SARS-CoV--induced cytopathic effects by preinfection or postinfection treatment with IFN-β 1a was dramatic, even at 72 h postinfection ([Figure 2](#F2){ref-type="fig"}). Additional concentrations of IFN-β 1a (0.5--5,000 IU/mL) were tested to determine the 50% inhibitory concentration (IC~50)~. Pretreatment of Vero E-6 cells with concentrations as low as 50 IU/mL, or posttreatment of cells with concentrations at 500 IU/mL, provided a 50% reduction with the Tor2 isolate at 24 h postinfection.

![Interferon (IFN)-β 1a inhibition of SARS-CoV replication in Vero E-6 cells. Top panels, Vero E-6 cells were incubated in the absence (-▲-) or presence of IFN-β 1a added 24 h before infection with the Tor2 (left) or Tor7 (right) isolate of SARS Co-V. Bottom panels, Vero E-6 cells were incubated in the absence (-▲-) or presence of IFN-β 1a added 1 h after infection with the Tor2 (left) or Tor7 (right) isolate of SARS Co-V. Three concentrations of IFN-β 1a were employed for both studies: 5,000 IU/mL (-□-), 50,000 IU/mL (-■-), 500,000 IU/mL (-■-) Samples of overlying media were collected at 24, 48, and 72 h postinfection and analyzed by plaque assay on Vero E-6 cells.](03-0482-F1){#F1}

![Interferon (IFN)-β 1a inhibition of SARS-CoV cytopathicity in Vero E-6 cells. Vero E-6 cells were infected with the Tor2 isolate of SARS-CoV and incubated for 72 h in the absence (left panel) or presence (right panel) of 500,000 IU of recombinant human IFN-β 1a. Cell rounding and detachment were prominent in the absence of IFN-β 1a. Minimal cell rounding or death was noted in the intact monolayer at 72 h postinoculation in the presence of IFN-β 1a (note: IFN-β 1a administered 1 h postinfection).](03-0482-F2){#F2}

Faced with a burgeoning epidemic of SARS cases and a lack of effective treatment options, identifying compounds with antiviral activity that could be potential therapeutics has become a high priority. Our report suggests that IFN-β 1a may be effective as a treatment for SARS-CoV infections. As noted above, IFN-β 1a is currently being used for a variety of clinical indications, including multiple sclerosis, and has shown dose-dependent efficacy in several clinical trials. Importantly, IFN-β 1a exhibited potent antiviral activity at doses that have already been shown to have acceptable safety profiles in animals ([@R10]). Thus, we report the identification of a compound that may be suitable for rapid development as a treatment for SARS-CoV infection.
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